The Ancient Drug Salicylate Indirectly Targets Fructose‐1,6‐Bisphosphatase to Suppress Liver Glucose Production in Diet‐Induced Obese Mice.
Saved in:
| Title: | The Ancient Drug Salicylate Indirectly Targets Fructose‐1,6‐Bisphosphatase to Suppress Liver Glucose Production in Diet‐Induced Obese Mice. |
|---|---|
| Authors: | Nisr, Raid B. (AUTHOR), Atrih, Abdelmadjid (AUTHOR), Lara, Erika J. Gutierrez (AUTHOR), Lamont, Douglas (AUTHOR), Luda, Katarzyna M. (AUTHOR), McCrimmon, Rory J. (AUTHOR), Sakamoto, Kei (AUTHOR), Rena, Graham (AUTHOR), McNeilly, Alison D. (AUTHOR) |
| Source: | Acta Physiologica. Jun2025, Vol. 241 Issue 6, p1-12. 12p. |
| Subjects: | Salicylates, Diabetes, Obesity, Glucose synthesis, Blood sugar, Energy metabolism, Metabolic regulation, Adenosine monophosphate |
| Abstract: | Aims: The benefit of salicylate in the treatment of diabetes has been recognized for over a century; however, challenging side effects have prevented widespread use. A better understanding of the relevant enzyme targets mediating its anti‐hyperglycaemic effect may lead to the development of novel therapies for diabetes. Here, we investigated the contribution of 5′‐adenosine monophosphate (AMP)‐dependent inhibition of fructose‐1,6‐bisphosphatase 1 (FBP1) to the anti‐hyperglycaemic action of salicylate. Methods: We studied AMP‐insensitive FBP1 G27P knockin (KI) mice through a variety of cellular approaches, including proteomics, Seahorse metabolic analysis, glucose production, and other assays, in addition to a detailed assessment of metabolic responses in vivo. Results: Compared with wild‐type littermates, AMP‐insensitive FBP1 KI mice were resistant to the effects of the drug on body weight, glucose tolerance, pyruvate disposal, liver lipid content and hepatic glucose production. Compared with wild‐type, KI hepatocytes exhibited baseline differences in glycolytic, TCA cycle and fatty acid oxidation enzyme levels, potentially linking gluconeogenic dysregulation and its reversal to non‐carbohydrate fuel management. Conclusion: Collectively, our data highlight a novel mechanism of action for the effects of salicylate on glycaemia and weight gain, which depends on AMP‐mediated allosteric inhibition of FBP1. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Physiologica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Aims: The benefit of salicylate in the treatment of diabetes has been recognized for over a century; however, challenging side effects have prevented widespread use. A better understanding of the relevant enzyme targets mediating its anti‐hyperglycaemic effect may lead to the development of novel therapies for diabetes. Here, we investigated the contribution of 5′‐adenosine monophosphate (AMP)‐dependent inhibition of fructose‐1,6‐bisphosphatase 1 (FBP1) to the anti‐hyperglycaemic action of salicylate. Methods: We studied AMP‐insensitive FBP1 G27P knockin (KI) mice through a variety of cellular approaches, including proteomics, Seahorse metabolic analysis, glucose production, and other assays, in addition to a detailed assessment of metabolic responses in vivo. Results: Compared with wild‐type littermates, AMP‐insensitive FBP1 KI mice were resistant to the effects of the drug on body weight, glucose tolerance, pyruvate disposal, liver lipid content and hepatic glucose production. Compared with wild‐type, KI hepatocytes exhibited baseline differences in glycolytic, TCA cycle and fatty acid oxidation enzyme levels, potentially linking gluconeogenic dysregulation and its reversal to non‐carbohydrate fuel management. Conclusion: Collectively, our data highlight a novel mechanism of action for the effects of salicylate on glycaemia and weight gain, which depends on AMP‐mediated allosteric inhibition of FBP1. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 17481708 |
| DOI: | 10.1111/apha.70058 |
